Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis

References

• Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003; 120: 542–547
   PubMed Web of Science ®Google Scholar
• White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 1996; 22: 695–708
   PubMed Web of Science ®Google Scholar
• Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1996; 22: 709–735
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007; 26: 5541–5552
   PubMed Web of Science ®Google Scholar
• Zhang X, Wharton W, Yuan Z, Tsai SC, Olashaw N, Seto E. Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Mol Cell Biol 2004; 24: 5106–5118
   PubMedGoogle Scholar
• de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 2003; 370: 737–749
   PubMed Web of Science ®Google Scholar
• Yang XJ, Gregoire S. Class II histone deacetylases: From sequence to function, regulation, and clinical implication. Mol Cell Biol 2005; 25: 2873–2884
   PubMed Web of Science ®Google Scholar
• Porcu M, Chiarugi A. The emerging therapeutic potential of sirtuin-interacting drugs: From cell death to lifespan extension. Trends Pharmacol Sci 2005; 26: 94–103
   PubMed Web of Science ®Google Scholar
• Mahlknecht U, Will J, Varin A, Hoelzer D, Herbein G. Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression. J Immunol 2004; 173: 3979–3990
   PubMedGoogle Scholar
• Herranz M, Esteller M. New therapeutic targets in cancer: The epigenetic connection. Clin Transl Oncol 2006; 8: 242–249
   PubMedGoogle Scholar
• Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000; 184: 1–16
   PubMed Web of Science ®Google Scholar
• Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 2003; 310: 529–536
   PubMed Web of Science ®Google Scholar
• Johnstone RW. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287–299
   PubMed Web of Science ®Google Scholar
• Chung YL, Lee MY, Wang AJ, Yao LF. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003; 8: 707–717
   PubMed Web of Science ®Google Scholar
• Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 2004; 10: 2289–2298
   PubMed Web of Science ®Google Scholar
• Huang L. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol 2006; 209: 611–616
   PubMedGoogle Scholar
• Bode KA, Schroder K, Hume DA, Ravasi T, Heeg K, Sweet MJ, et al. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 2007; 122: 596–606
   PubMed Web of Science ®Google Scholar
• Adcock IM. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 2007; 150: 829–831
   PubMed Web of Science ®Google Scholar
• Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007; 150: 862–872
   PubMed Web of Science ®Google Scholar
• Huang N, Katz JP, Martin DR, Wu GD. Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. Cytokine 1997; 9: 27–36
   PubMed Web of Science ®Google Scholar
• Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003; 111: 539–552
   PubMed Web of Science ®Google Scholar
• Reilly CM, Mishra N, Miller JM, Joshi D, Ruiz P, Richon VM, et al. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol 2004; 173: 4171–4178
   PubMed Web of Science ®Google Scholar
• Huber LC, Distler JH, Moritz F, Hemmatazad H, Hauser T, Michel BA, et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum 2007; 56: 2755–2764
   PubMed Web of Science ®Google Scholar
• Shebzukhov YV, Koroleva EP, Khlgatian SV, Belousov PV, Kuz'mina KE, Radko BV, et al. Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients. Int J Cancer 2005; 117: 800–806
   PubMed Web of Science ®Google Scholar
• Masi AT, Rodnan GP, Medsger TA. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581–590
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr., et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202–205
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF. The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403–407
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344–347
   PubMed Web of Science ®Google Scholar
• Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000; 165: 6635–6643
   PubMed Web of Science ®Google Scholar
• Miyakawa H, Kikuchi K, Kitazawa E, Kawaguchi N. Anti-pyruvate dehydrogenase complex-E2 antibody immunoglobulin class switch from IgM to IgG in long-term follow-up patients with primary biliary cirrhosis. Hepatol Res 2002; 22: 167–173
   Google Scholar
• Liu S, Cerutti A, Casali P, Crow MK. Ongoing immunoglobulin class switch DNA recombination in lupus B cells: Analysis of switch regulatory regions. Autoimmunity 2004; 37: 431–443
   PubMed Web of Science ®Google Scholar
• Phan TG, Amesbury M, Gardam S, Crosbie J, Hasbold J, Hodgkin PD, et al. B cell receptor-independent stimuli trigger immunoglobulin (Ig) class switch recombination and production of IgG autoantibodies by anergic self-reactive B cells. J Exp Med 2003; 197: 845–860
   Google Scholar
• Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, Doi H, et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum 2004; 50: 3365–3376
   PubMed Web of Science ®Google Scholar
• Stephanie Gu Y, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The Immunobiology of Systemic Sclerosis. Semin Arthritis Rheum 2008; 38: 132–160
   Google Scholar
• Shoenfeld Y, Toubi E. Protective autoantibodies: Role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum 2005; 52: 2599–2606
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Isenberg DA. The mosaic of autoimmunity. Immunol Today 1989; 10: 123–126
   PubMedGoogle Scholar
• Bootsma H, Spronk PE, Hummel EJ, de Boer G, ter Borg EJ, Limburg PC, et al. Anti-double stranded DNA antibodies in systemic lupus erythematosus: Detection and clinical relevance of IgM-class antibodies. Scand J Rheumatol 1996; 25: 352–359
   PubMed Web of Science ®Google Scholar
• Tarkowski A, Westberg G. Rheumatoid factor isotypes and renal disease in systemic lupus erythematosus. Scand J Rheumatol 1987; 16: 309–312
   PubMed Web of Science ®Google Scholar
• Malik S, Bruner GR, Williams-Weese C, Feo L, Scofield RH, Reichlin M, et al. Presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures in lupus patients. Lupus 2007; 16: 863–866
   Google Scholar